EA201591015A1 - Жидкие фармацевтические наноэмульсионные составы для местного применения - Google Patents

Жидкие фармацевтические наноэмульсионные составы для местного применения

Info

Publication number
EA201591015A1
EA201591015A1 EA201591015A EA201591015A EA201591015A1 EA 201591015 A1 EA201591015 A1 EA 201591015A1 EA 201591015 A EA201591015 A EA 201591015A EA 201591015 A EA201591015 A EA 201591015A EA 201591015 A1 EA201591015 A1 EA 201591015A1
Authority
EA
Eurasian Patent Office
Prior art keywords
active ingredient
liquid pharmaceutical
local application
emulsion compositions
equal
Prior art date
Application number
EA201591015A
Other languages
English (en)
Russian (ru)
Inventor
Фредерик Л. Джордан
Крис Джордан
Original Assignee
ДжейАрИкс БИОТЕКНОЛОДЖИ, ИНК.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ДжейАрИкс БИОТЕКНОЛОДЖИ, ИНК. filed Critical ДжейАрИкс БИОТЕКНОЛОДЖИ, ИНК.
Publication of EA201591015A1 publication Critical patent/EA201591015A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Anesthesiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
EA201591015A 2012-12-31 2013-12-27 Жидкие фармацевтические наноэмульсионные составы для местного применения EA201591015A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261748036P 2012-12-31 2012-12-31
US201361758726P 2013-01-30 2013-01-30
PCT/US2013/077985 WO2014106048A2 (en) 2012-12-31 2013-12-27 Liquid topical pharmaceutical nano-emulsion formulations

Publications (1)

Publication Number Publication Date
EA201591015A1 true EA201591015A1 (ru) 2016-05-31

Family

ID=51022202

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591015A EA201591015A1 (ru) 2012-12-31 2013-12-27 Жидкие фармацевтические наноэмульсионные составы для местного применения

Country Status (10)

Country Link
US (2) US20150374835A1 (enExample)
EP (1) EP2938324B1 (enExample)
JP (1) JP6403686B2 (enExample)
KR (1) KR20150102058A (enExample)
CN (2) CN110201180A (enExample)
BR (1) BR112015015788A2 (enExample)
EA (1) EA201591015A1 (enExample)
ES (1) ES2969933T3 (enExample)
SG (1) SG11201505076UA (enExample)
WO (1) WO2014106048A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10596117B1 (en) 2014-12-31 2020-03-24 Eric Morrison Lipoleosomes as carriers for aromatic amide anesthetic compounds
US11007161B1 (en) 2014-12-31 2021-05-18 Eric Morrison Ibuprofen nanoparticle carriers encapsulated with hermatic surfactant films
US10561627B2 (en) 2014-12-31 2020-02-18 Eric Morrison Ibuprofen nanoparticle carriers encapsulated with hermetic surfactant films
KR20180053318A (ko) * 2015-09-17 2018-05-21 제이알엑스 바이오테크놀로지, 인코포레이티드 피부 수화 또는 보습을 향상시키기 위한 접근법
WO2018063828A1 (en) 2016-09-29 2018-04-05 Jrx Biotechnology, Inc. Methods and compositions for modifying plant growth and reducing water consumption by plants
PL3558269T3 (pl) 2016-12-21 2024-11-18 Dukebox Spółka Z Ograniczoną Odpowiedzialnością Sposób wytwarzania emulsji woda w oleju nanocząsteczek paracetamolu
BR112020019592A2 (pt) * 2018-03-28 2021-01-05 Jrx Biotechnology, Inc. Composições agrícolas
KR102117651B1 (ko) 2018-04-27 2020-06-02 대구가톨릭대학교산학협력단 항산화, 주름개선 또는 염증개선용 한방 조성물 및 이를 포함하는 화장료 조성물

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4374766A (en) 1982-06-01 1983-02-22 Charles Of The Ritz Group Ltd. Combined allantoin-hydrolyzed animal protein product and method
US4973473A (en) 1989-06-23 1990-11-27 Revlon, Inc. Skin care preparation
IT1232318B (it) 1989-09-07 1992-01-28 Crinos Industria Farmaco Composizioni ad uso topico contenenti acidi nucleici depolimerizzati per la cosmesi della pelle e del corpo.
US5153174A (en) 1989-10-30 1992-10-06 Union Carbide Chemicals & Plastics Inc. Polymer mixtures useful in skin care
CA2096242A1 (en) 1990-11-14 1992-05-15 Peter Ghosh Anti-inflammatory composition derived from emu oil
US5297562A (en) 1991-04-01 1994-03-29 President And Fellows Of Harvard College Method for detecting and treating Alzheimer's disease
IL101387A (en) 1992-03-26 1999-11-30 Pharmos Ltd Emulsion with enhanced topical and/or transdermal systemic effect utilizing submicron oil droplets
US5614212A (en) 1992-04-08 1997-03-25 International Medical Associates, Inc. Method of transdermally administering high molecular weight drugs with a polymer skin enhancer
US5318960A (en) 1992-06-03 1994-06-07 Frank Toppo System for transdermal delivery of pain relieving substances
KR940021073A (ko) 1993-03-02 1994-10-17 미야베 요시가즈 알쯔하이머병의 예방 또는 치료제, 그 스크리닝 방법 및 인간 유래의 타우 단백질 키나아제 i
US6113921A (en) * 1993-03-23 2000-09-05 Pharmos Corp. Topical and transdermal delivery system utilizing submicron oil spheres
US6103246A (en) 1993-06-03 2000-08-15 Tisdale; Carrie J. Creams and lotions containing emu oil
US5840746A (en) 1993-06-24 1998-11-24 Merck Frosst Canada, Inc. Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
US5744155A (en) 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
US5744368A (en) 1993-11-04 1998-04-28 Research Foundation Of State University Of New York Methods for the detection of soluble amyloid β-protein (βAP) or soluble transthyretin (TTR)
US5665378A (en) 1994-09-30 1997-09-09 Davis; Roosevelt Transdermal therapeutic formulation
US5472713A (en) 1994-11-23 1995-12-05 Elf Resources, Inc. Therapeutic uses of emu oil
US5716625A (en) 1994-12-21 1998-02-10 Cosmederm Technologies Formulations and methods for reducing skin irritation
US5744128A (en) 1995-05-03 1998-04-28 Holick; Michael F. Use of emu oil for stimulating skin and hair growth
AUPN531195A0 (en) 1995-09-11 1995-10-05 J.W. Broadbent Nominees Pty. Ltd. Lipid extract having anti-inflamatory activity
US5939082A (en) 1995-11-06 1999-08-17 The Procter & Gamble Company Methods of regulating skin appearance with vitamin B3 compound
IT1289845B1 (it) 1996-01-10 1998-10-16 Guido Paduano Formula per il trattamento della cute e suoi impieghi
US5891857A (en) 1996-02-20 1999-04-06 Vanderbilt University Characterized BRCA1 and BRCA2 proteins and screening and therapeutic methods based on characterized BRCA1 and BRCA2 proteins
EP0883433B1 (en) 1996-03-01 2002-09-11 Ebara Corporation Desulfurizing method and apparatus by irradiation of electron beam
US5891651A (en) 1996-03-29 1999-04-06 Mayo Foundation For Medical Education And Research Methods of recovering colorectal epithelial cells or fragments thereof from stool
US5861268A (en) 1996-05-23 1999-01-19 Biomide Investment Limited Partnership Method for induction of tumor cell apoptosis with chemical inhibitors targeted to 12-lipoxygenase
US5708038A (en) 1996-06-13 1998-01-13 Univera Pharmaceuticals, Inc. Method of using aloe vera as a biological vehicle
US5698227A (en) 1996-07-23 1997-12-16 Rivlin; Daniel Compositions comprising lidocaine and emu oil and methods of use thereof
WO1998029085A2 (en) 1996-12-31 1998-07-09 American Medical Research, L.L.C. Skin product having continuing antimicrobial, antiviral, antiseptic, and healing properties
AU6046198A (en) 1997-01-31 1998-08-25 Kenneth Hoyt Use of oil from emu or rhea birds as trans-membrane carriers for delivery of drugs, peptides and vaccines
US5945446A (en) 1997-02-10 1999-08-31 Laubc Biochemicals, Corporation Process for preparing synthetic soil-extract materials and medicaments based thereon
DK0999826T3 (da) 1997-07-29 2004-07-26 Upjohn Co Selv-emulgerende formulering til lipofile forbindelser
US5885597A (en) 1997-10-01 1999-03-23 Medical Research Industries,Inc. Topical composition for the relief of pain
ID25908A (id) 1998-03-06 2000-11-09 Novartis Ag Prakonsentrat-prakonsentrat emulsi yang mengandung siklosporin atau makrolida
EP1075252A2 (en) 1998-05-07 2001-02-14 ELAN CORPORATION, Plc Solvent/cosolvent free microemulsion and emulsion preconcentrate drug delivery systems
TW537894B (en) * 1998-05-26 2003-06-21 Novartis Ag A spontaneously dispersible pharmaceutical composition comprising a piperidine substance P antagonist
DE69939019D1 (de) 1998-07-07 2008-08-14 Transdermal Technologies Inc Zusammensetzungen für die schnelle und nicht-irritierende transdermale verabreichung von pharmazeutika and verfahren zur formuliering davon und ihren verabreichung
US7220427B2 (en) 1998-07-08 2007-05-22 Oryxe Mixture for transdermal delivery of low and high molecular weight compounds
US6946144B1 (en) 1998-07-08 2005-09-20 Oryxe Transdermal delivery system
WO2000002601A2 (en) 1998-07-08 2000-01-20 Oryxe Transdermal delivery system
FR2787703B1 (fr) * 1998-12-29 2001-01-26 Oreal Nanoemulsion a base d'ethers gras ethoxyles ou d'esters gras ethoxyles, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
US20060121103A1 (en) 2000-05-11 2006-06-08 Kenneth Kirby Transdermal delivery system
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
AU2004283067A1 (en) 2003-10-10 2005-05-06 Oryxe Transdermal high and low molecular weight compounds
DK1765310T3 (en) * 2004-05-28 2016-01-11 Oryxe MIXING for transdermal delivery of LAV AND HØJMOLEKYLVÆGTFORBINDELSER
CA2566354C (en) 2004-05-28 2016-01-12 Oryxe A mixture for transdermal delivery of low and high molecular weight compounds
US20050271752A1 (en) * 2004-06-04 2005-12-08 Roth Ivar E Antifungal products and method of use
US8338648B2 (en) * 2004-06-12 2012-12-25 Signum Biosciences, Inc. Topical compositions and methods for epithelial-related conditions
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
JP4974903B2 (ja) 2005-02-09 2012-07-11 参天製薬株式会社 疾患または状態を処置するための液体処方物
US7371738B2 (en) * 2005-04-15 2008-05-13 University Of South Florida Method of transdermal drug delivery using hyaluronic acid nanoparticles
US20070264346A1 (en) 2006-02-16 2007-11-15 Flamel Technologies Multimicroparticulate pharmaceutical forms for oral administration
CA2645080A1 (en) 2006-03-07 2007-09-13 Novavax,Inc. Nanoemulsions of poorly soluble pharmaceutical active ingredients and methods of making the same
EP2170961A1 (de) * 2007-07-25 2010-04-07 S & V Technologies AG Hyaluronsäuredispersion, herstellung und anwendung
GB2451811A (en) * 2007-08-09 2009-02-18 Ems Sa Delivery composition for solubilising water-insoluble pharmaceutical active ingredients
DE102008034944B4 (de) * 2008-07-26 2017-03-16 Arivine Pharma Ag Mikroemulsion
CN102389401B (zh) 2011-11-22 2013-05-22 陆荣政 一种右旋布洛芬颗粒及其制备方法

Also Published As

Publication number Publication date
CN105209011A (zh) 2015-12-30
US12285487B2 (en) 2025-04-29
US20150374835A1 (en) 2015-12-31
EP2938324A4 (en) 2016-09-28
WO2014106048A2 (en) 2014-07-03
KR20150102058A (ko) 2015-09-04
BR112015015788A2 (pt) 2017-07-11
CN110201180A (zh) 2019-09-06
ES2969933T3 (es) 2024-05-23
US20200009257A1 (en) 2020-01-09
EP2938324A2 (en) 2015-11-04
HK1216719A1 (en) 2016-12-02
EP2938324B1 (en) 2023-11-08
WO2014106048A3 (en) 2014-08-21
JP6403686B2 (ja) 2018-10-10
HK1218723A1 (zh) 2017-03-10
JP2016508141A (ja) 2016-03-17
CN105209011B (zh) 2019-06-25
SG11201505076UA (en) 2015-07-30

Similar Documents

Publication Publication Date Title
EA201591015A1 (ru) Жидкие фармацевтические наноэмульсионные составы для местного применения
Tachtsis et al. Potential roles of n-3 PUFAs during skeletal muscle growth and regeneration
CL2017001115A1 (es) Formulación estable de proteina en solución que contiene una alta concentración de un anticuerpo anti-vegf.
JP2016503398A5 (enExample)
ECSP17032530A (es) Nuevos indazoles sustituidos, procedimientos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos
Nouwen et al. Pathogens MenTORing macrophages and dendritic cells: manipulation of mTOR and cellular metabolism to promote immune escape
EP3297434A4 (en) Non-aqueous organo liquid delivery systems containing dispersed poly (organic acids) that improve availability of macro&micro-nutrients to plants
Bernatoniene et al. Novel drug targets and emerging pharmacotherapies in neuropathic pain
AR102198A1 (es) Proceso para reducir partículas subvisibles en una formulación farmacéutica
MX2012007794A (es) Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleuquina-6 (il-6r).
BR112015000203A2 (pt) formulações de etanercept que exibem redução marcada em partículas sub-visíveis
Lanchais et al. Could omega 3 fatty acids preserve muscle health in rheumatoid arthritis?
Ueno et al. Omega-3 polyunsaturated fatty acids and stroke burden
Morotti et al. Platelet redox imbalance in hypercholesterolemia: a big problem for a small cell
Takeda et al. Modulatory mechanism of nociceptive neuronal activity by dietary constituent resveratrol
WO2017037075A8 (de) Zusammensetzung enthaltend einen extrakt aus echinacea und linolsäurederivate
Mkhize et al. The relationship between renin–angiotensin–aldosterone system (RAAS) activity, osteoporosis and estrogen deficiency in type 2 diabetes
Palcsó et al. Different types, applications and limits of enabling excipients of pharmaceutical dosage forms
Lessa et al. Oral mucositis in cancer and potential use of Omega-3 free fatty acids in its management: A review
Miranda‐Lara et al. Synergistic interaction between docosahexaenoic acid and diclofenac on inflammation, nociception, and gastric security models in rats
WO2016075704A3 (en) Stable topical pharmaceutical compositions comprising gabapentin
EP2852399A4 (en) LEDGF PEPTIDES AND FORMULATIONS THEREFOR FOR THE TREATMENT OF DEGENERATIVE DISEASES
PT4081502T (pt) Co-cristal de cetoprofeno e a sua preparação, composições farmacêuticas compreendendo o mesmo e suas utilizações
Stabrauskiene et al. Development and Evaluation of an Anti-Inflammatory Emulsion: Skin Penetration, Physicochemical Properties, and Fibroblast Viability Assessment
Simos et al. Bone-targeted agents for the management of breast cancer patients with bone metastases